Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

MET ectodomain shedding is associated with poor disease-free survival of patients diagnosed with oral squamous cell carcinoma.

De Herdt MJ, Koljenović S, van der Steen B, Willems SM, Noorlag R, Nieboer D, Hardillo JA, Gruver AM, Zeng W, Liu L, de Jong RJB, Looijenga LH.

Mod Pathol. 2019 Dec 19. doi: 10.1038/s41379-019-0426-2. [Epub ahead of print]

PMID:
31857683
2.

Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data.

Lobo J, Gillis AJM, van den Berg A, Dorssers LCJ, Belge G, Dieckmann KP, Roest HP, van der Laan LJW, Gietema J, Hamilton RJ, Jerónimo C, Henrique R, Salvatori D, Looijenga LHJ.

Cells. 2019 Dec 14;8(12). pii: E1637. doi: 10.3390/cells8121637.

3.

Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.

Blok JM, Pluim I, Daugaard G, Wagner T, Jóźwiak K, Wilthagen EA, Looijenga LHJ, Meijer RP, Bosch JLHR, Horenblas S.

BJU Int. 2020 Mar;125(3):355-368. doi: 10.1111/bju.14967. Epub 2020 Jan 8. Review.

PMID:
31797520
4.

MicroRNA Profiling in Benign and Malignant Conjunctival Melanocytic Lesions.

van Ipenburg JA, Gillis Ing AJM, Dorssers LCJ, van den Bosch QCC, van Ginderdeuren R, Missotten GS, Naus N, Paridaens D, Looijenga LHJ, Verdijk RM.

Ophthalmology. 2019 Oct 12. pii: S0161-6420(19)32142-6. doi: 10.1016/j.ophtha.2019.10.008. [Epub ahead of print] No abstract available.

PMID:
31767433
5.

Meiotic arrest occurs most frequently at metaphase and is often incomplete in azoospermic men.

Enguita-Marruedo A, Sleddens-Linkels E, Ooms M, de Geus V, Wilke M, Blom E, Dohle GR, Looijenga LHJ, van Cappellen W, Baart EB, Baarends WM.

Fertil Steril. 2019 Dec;112(6):1059-1070.e3. doi: 10.1016/j.fertnstert.2019.08.004. Epub 2019 Nov 22.

6.

The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells.

Camacho-Moll ME, Macdonald J, Looijenga LHJ, Rimmer MP, Donat R, Marwick JA, Shukla CJ, Carragher N, Jørgensen A, Mitchell RT.

BMC Cancer. 2019 Nov 19;19(1):1124. doi: 10.1186/s12885-019-6340-7.

7.

Predicting Gonadal Germ Cell Cancer in People with Disorders of Sex Development; Insights from Developmental Biology.

Looijenga LHJ, Kao CS, Idrees MT.

Int J Mol Sci. 2019 Oct 10;20(20). pii: E5017. doi: 10.3390/ijms20205017. Review.

8.

miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.

Rosas Plaza X, van Agthoven T, Meijer C, van Vugt MATM, de Jong S, Gietema JA, Looijenga LHJ.

Cells. 2019 Oct 8;8(10). pii: E1221. doi: 10.3390/cells8101221.

9.

XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality.

Lobo J, Nunes SP, Gillis AJM, Barros-Silva D, Miranda-Gonçalves V, Berg AVD, Cantante M, Guimarães R, Henrique R, Jerónimo C, Looijenga LHJ.

Cancers (Basel). 2019 Sep 17;11(9). pii: E1385. doi: 10.3390/cancers11091385.

10.

Interobserver Agreement in Vascular Invasion Scoring and the Added Value of Immunohistochemistry for Vascular Markers to Predict Disease Relapse in Stage I Testicular Nonseminomas.

Lobo J, Stoop H, Gillis AJM, Looijenga LHJ, Oosterhuis W.

Am J Surg Pathol. 2019 Dec;43(12):1711-1719. doi: 10.1097/PAS.0000000000001352.

PMID:
31490238
11.

SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma.

Hopman ANH, Moshi JM, Hoogduin KJ, Ummelen M, Henfling MER, van Engeland M, Wouters KAD, Stoop H, Looijenga LHJ, Ramaekers FCS.

Histopathology. 2020 Feb;76(3):383-393. doi: 10.1111/his.13980. Epub 2019 Dec 1.

PMID:
31444787
12.

Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss.

Lobo J, Pinto C, Pinheiro M, Lobo F, Sousa N, Lopes P, Looijenga LH, Jerónimo C, Teixeira MR, Henrique R.

Histopathology. 2020 Feb;76(3):486-489. doi: 10.1111/his.13979. Epub 2019 Nov 13. No abstract available.

PMID:
31442315
13.

Ectopic activation of WNT signaling in human embryonal carcinoma cells and its effects in short- and long-term in vitro culture.

Atlasi Y, van Dorsten RT, Sacchetti A, Joosten R, Oosterhuis JW, Looijenga LHJ, Fodde R.

Sci Rep. 2019 Aug 15;9(1):11928. doi: 10.1038/s41598-019-48396-7.

14.

Human germ cell tumours from a developmental perspective.

Oosterhuis JW, Looijenga LHJ.

Nat Rev Cancer. 2019 Sep;19(9):522-537. doi: 10.1038/s41568-019-0178-9. Epub 2019 Aug 14. Review.

PMID:
31413324
15.

Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma.

Suzuki L, Ten Kate FJC, Gotink AW, Stoop H, Doukas M, Nieboer D, Spaander MCW, van Lanschot JJB, van Wijnhoven BPL, Koch AD, Bruno MJ, Looijenga LHJ, Biermann K.

PLoS One. 2019 Jul 8;14(7):e0219494. doi: 10.1371/journal.pone.0219494. eCollection 2019.

16.

Response to Letter to the Editor: "Clinical but Not Histological Outcomes in Males With 45,X/46,XY Mosaicism Vary Depending on Reason for Diagnosis".

Ljubicic ML, Jørgensen A, Ribeiro de Andrade JG, Balsamo A, Bertelloni S, Cools M, Cuccaro RT, Darendeliler F, Flück CE, Grinspon RP, Maciel-Guerra A, Guran T, Hannema SE, Lucas-Herald AK, Hiort O, Holterhus PM, Lichiardopol C, Looijenga LHJ, Ortolano R, Riedl S, Ahmed SF, Juul A.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):5812-5813. doi: 10.1210/jc.2019-01413. No abstract available.

PMID:
31276168
17.

Clinical but Not Histological Outcomes in Males With 45,X/46,XY Mosaicism Vary Depending on Reason for Diagnosis.

Ljubicic ML, Jørgensen A, Acerini C, Andrade J, Balsamo A, Bertelloni S, Cools M, Cuccaro RT, Darendeliler F, Flück CE, Grinspon RP, Maciel-Guerra A, Guran T, Hannema SE, Lucas-Herald AK, Hiort O, Holterhus PM, Lichiardopol C, Looijenga LHJ, Ortolano R, Riedl S, Ahmed SF, Juul A.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4366-4381. doi: 10.1210/jc.2018-02752.

PMID:
31127831
18.

Do pathologists agree with each other on the histological assessment of pT1b oesophageal adenocarcinoma?

Gotink AW, Ten Kate FJ, Doukas M, Wijnhoven BP, Bruno MJ, Looijenga LH, Koch AD, Biermann K.

United European Gastroenterol J. 2019 Mar;7(2):261-269. doi: 10.1177/2050640618817693. Epub 2018 Dec 6.

19.

Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.

Boellaard WPA, Gillis AJM, van Leenders GJLH, Stoop H, van Agthoven T, Dorssers LCJ, Dinkelman-Smit M, Boormans JL, Looijenga LHJ.

Andrology. 2019 Jul;7(4):463-468. doi: 10.1111/andr.12595. Epub 2019 Feb 20.

20.

Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development.

Dorssers LCJ, Gillis AJM, Stoop H, van Marion R, Nieboer MM, van Riet J, van de Werken HJG, Oosterhuis JW, de Ridder J, Looijenga LHJ.

Br J Cancer. 2019 Feb;120(4):444-452. doi: 10.1038/s41416-019-0381-1. Epub 2019 Feb 11.

21.

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic.

Lobo J, Gillis AJM, Jerónimo C, Henrique R, Looijenga LHJ.

Int J Mol Sci. 2019 Jan 10;20(2). pii: E258. doi: 10.3390/ijms20020258. Review.

22.

Correction: c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors.

Scheri KC, Leonetti E, Laino L, Gigantino V, Gesualdi L, Grammatico P, Bizzarri M, Franco R, Oosterhuis JW, Stoop H, Looijenga LHJ, Ricci G, Catizone A.

Oncotarget. 2018 Nov 13;9(89):36049. doi: 10.18632/oncotarget.26374. eCollection 2018 Nov 13.

23.

Clinical utility of plasma miR-371a-3p in germ cell tumors.

Mego M, van Agthoven T, Gronesova P, Chovanec M, Miskovska V, Mardiak J, Looijenga LHJ.

J Cell Mol Med. 2019 Feb;23(2):1128-1136. doi: 10.1111/jcmm.14013. Epub 2018 Dec 7.

24.

The MicroRNA-371 Family as Plasma Biomarkers for Monitoring Undifferentiated and Potentially Malignant Human Pluripotent Stem Cells in Teratoma Assays.

Salvatori DCF, Dorssers LCJ, Gillis AJM, Perretta G, van Agthoven T, Gomes Fernandes M, Stoop H, Prins JB, Oosterhuis JW, Mummery C, Looijenga LHJ.

Stem Cell Reports. 2018 Dec 11;11(6):1493-1505. doi: 10.1016/j.stemcr.2018.11.002. Epub 2018 Nov 29.

25.

TargetClone: A multi-sample approach for reconstructing subclonal evolution of tumors.

Nieboer MM, Dorssers LCJ, Straver R, Looijenga LHJ, de Ridder J.

PLoS One. 2018 Nov 29;13(11):e0208002. doi: 10.1371/journal.pone.0208002. eCollection 2018.

26.

Cell-free MicroRNA miR-505-3p in Graft Preservation Fluid Is an Independent Predictor of Delayed Graft Function After Kidney Transplantation.

Roest HP, Ooms LSS, Gillis AJM, IJzermans JNM, Looijenga LHJ, Dorssers LCJ, Dor FJMF, van der Laan LJW.

Transplantation. 2019 Feb;103(2):329-335. doi: 10.1097/TP.0000000000002527.

PMID:
30444806
27.

NR5A1 gene variants repress the ovarian-specific WNT signaling pathway in 46,XX disorders of sex development patients.

Knarston IM, Robevska G, van den Bergen JA, Eggers S, Croft B, Yates J, Hersmus R, Looijenga LHJ, Cameron FJ, Monhike K, Ayers KL, Sinclair AH.

Hum Mutat. 2019 Feb;40(2):207-216. doi: 10.1002/humu.23672. Epub 2018 Nov 30.

28.

Management of Gonads in Adults with Androgen Insensitivity: An International Survey.

Tack LJW, Maris E, Looijenga LHJ, Hannema SE, Audi L, Köhler B, Holterhus PM, Riedl S, Wisniewski A, Flück CE, Davies JH, T'Sjoen G, Lucas-Herald AK, Evliyaoglu O, Krone N, Iotova V, Marginean O, Balsamo A, Verkauskas G, Weintrob N, Ellaithi M, Nordenström A, Verrijn Stuart A, Kluivers KB, Wolffenbuttel KP, Ahmed SF, Cools M.

Horm Res Paediatr. 2018;90(4):236-246. doi: 10.1159/000493645. Epub 2018 Oct 18.

PMID:
30336477
29.

Testicular cancer.

Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, Looijenga LHJ.

Nat Rev Dis Primers. 2018 Oct 5;4(1):29. doi: 10.1038/s41572-018-0029-0. Review.

PMID:
30291251
30.

c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors.

Scheri KC, Leonetti E, Laino L, Gigantino V, Gesualdi L, Grammatico P, Bizzari M, Franco R, Oosterhuis JW, Stoop H, Looijenga LHJ, Ricci G, Catizone A.

Oncotarget. 2018 Aug 7;9(61):31842-31860. doi: 10.18632/oncotarget.25867. eCollection 2018 Aug 7. Erratum in: Oncotarget. 2018 Nov 13;9(89):36049.

31.

Improved Progression Prediction in Barrett's Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria.

Ten Kate FJC, Nieboer D, Ten Kate FJW, Doukas M, Bruno MJ, Spaander MCW, Looijenga LHJ, Biermann K; ProBar study group and Palga Group.

Am J Surg Pathol. 2018 Jul;42(7):918-926. doi: 10.1097/PAS.0000000000001066.

PMID:
29697438
32.

Serum microRNA profiles in athyroid patients on and off levothyroxine therapy.

Massolt ET, Chaker L, Visser TJ, Gillis AJM, Dorssers LCJ, Beukhof CM, Kam BLR, Franssen GJ, Brigante G, van Ginhoven TM, Visser WE, Looijenga LHJ, Peeters RP.

PLoS One. 2018 Apr 12;13(4):e0194259. doi: 10.1371/journal.pone.0194259. eCollection 2018.

33.

EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Chen KS, Fustino NJ, Shukla AA, Stroup EK, Budhipramono A, Ateek C, Stuart SH, Yamaguchi K, Kapur P, Frazier AL, Lum L, Looijenga LHJ, Laetsch TW, Rakheja D, Amatruda JF.

Mol Cancer Ther. 2018 May;17(5):1079-1089. doi: 10.1158/1535-7163.MCT-17-0137. Epub 2018 Feb 26.

34.

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ.

J Urol. 2018 Jul;200(1):126-135. doi: 10.1016/j.juro.2018.02.068. Epub 2018 Feb 21.

PMID:
29474847
35.

SNPitty: An Intuitive Web Application for Interactive B-Allele Frequency and Copy Number Visualization of Next-Generation Sequencing Data.

van Riet J, Krol NMG, Atmodimedjo PN, Brosens E, van IJcken WFJ, Jansen MPHM, Martens JWM, Looijenga LH, Jenster G, Dubbink HJ, Dinjens WNM, van de Werken HJG.

J Mol Diagn. 2018 Mar;20(2):166-176. doi: 10.1016/j.jmoldx.2017.11.011. Epub 2018 Jan 2.

36.

Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.

Ten Kate FJC, Suzuki L, Dorssers LCJ, Dinjens WNM, Jones DTW, Nieboer D, Doukas M, Van Lanschot JJB, Wijnhoven BPL, Looijenga LHJ, Biermann K.

Oncotarget. 2017 Oct 24;8(61):104123-104135. doi: 10.18632/oncotarget.22021. eCollection 2017 Nov 28.

37.

Biallelic and monoallelic ESR2 variants associated with 46,XY disorders of sex development.

Baetens D, Güran T, Mendonca BB, Gomes NL, De Cauwer L, Peelman F, Verdin H, Vuylsteke M, Van der Linden M; ESR2 STUDY GROUP, Atay Z, Bereket A, de Krijger RR, Preter K, Domenice S, Turan S, Stoop H, Looijenga LH, De Bosscher K, Cools M, De Baere E.

Genet Med. 2018 Jul;20(7):717-727. doi: 10.1038/gim.2017.163. Epub 2017 Oct 26.

PMID:
29261182
38.

A Rare Case of Embryonal Carcinoma in a Patient with Turner Syndrome without Y Chromosomal Material but Mutations in KIT, AKT1, and ZNF358 Demonstrated Using Exome Sequencing.

Gravholt CH, Dollerup OL, Duval L, Mejlgaard E, Stribolt K, Vang S, Laursen BE, Knudsen M, Thorsen K, Hersmus R, Looijenga LHJ, Stochholm K.

Sex Dev. 2017;11(5-6):262-268. doi: 10.1159/000484398. Epub 2017 Dec 2.

PMID:
29197878
39.

Histological Assessment of Gonads in DSD: Relevance for Clinical Management.

Spoor JA, Oosterhuis JW, Hersmus R, Biermann K, Wolffenbuttel KP, Cools M, Kazmi Z, Ahmed SF, Looijenga LHJ.

Sex Dev. 2018;12(1-3):106-122. doi: 10.1159/000481757. Epub 2017 Nov 3. Review.

PMID:
29131109
40.

Malignant testicular germ cell tumors in postpubertal individuals with androgen insensitivity: prevalence, pathology and relevance of single nucleotide polymorphism-based susceptibility profiling.

Cools M, Wolffenbuttel KP, Hersmus R, Mendonca BB, Kaprová J, Drop SLS, Stoop H, Gillis AJM, Oosterhuis JW, Costa EMF, Domenice S, Nishi MY, Wunsch L, Quigley CA, T'Sjoen G, Looijenga LHJ.

Hum Reprod. 2017 Dec 1;32(12):2561-2573. doi: 10.1093/humrep/dex300.

PMID:
29121256
41.

Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis.

Janmaat VT, van Olphen SH, Biermann KE, Looijenga LHJ, Bruno MB, Spaander MCW.

PLoS One. 2017 Oct 23;12(10):e0186305. doi: 10.1371/journal.pone.0186305. eCollection 2017. Review.

42.

Multiparameter Investigation of a 46,XX/46,XY Tetragametic Chimeric Phenotypical Male Patient with Bilateral Scrotal Ovotestes and Ovulatory Activity.

van Bever Y, Wolffenbuttel KP, Brüggenwirth HT, Blom E, de Klein A, Eussen BHJ, van der Windt F, Hannema SE, Dessens AB, Dorssers LCJ, Biermann K, Hersmus R, de Rijke YB, Looijenga LHJ.

Sex Dev. 2018;12(1-3):145-154. doi: 10.1159/000479946. Epub 2017 Sep 20.

43.

Adrenal Cushing's syndrome during pregnancy.

Andreescu CE, Alwani RA, Hofland J, Looijenga LHJ, de Herder WW, Hofland LJ, Feelders RA.

Eur J Endocrinol. 2017 Nov;177(5):K13-K20. doi: 10.1530/EJE-17-0263. Epub 2017 Aug 17.

PMID:
28819015
44.

VASA mRNA (DDX4) detection is more specific than immunohistochemistry using poly- or monoclonal antibodies for germ cells in the male urogenital tract.

Boellaard WPA, Stoop H, Gillis AJM, Oosterhuis JW, Looijenga LHJ.

Medicine (Baltimore). 2017 Jul;96(30):e7489. doi: 10.1097/MD.0000000000007489.

45.

Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.

Ten Kate FJC, van Olphen SH, Bruno MJ, Wijnhoven BPL, van Lanschot JJB, Looijenga LHJ, Fitzgerald RC, Biermann K.

Br J Surg. 2017 Sep;104(10):1327-1337. doi: 10.1002/bjs.10553. Epub 2017 Jul 10.

46.

DOC1-Dependent Recruitment of NURD Reveals Antagonism with SWI/SNF during Epithelial-Mesenchymal Transition in Oral Cancer Cells.

Mohd-Sarip A, Teeuwssen M, Bot AG, De Herdt MJ, Willems SM, Baatenburg de Jong RJ, Looijenga LHJ, Zatreanu D, Bezstarosti K, van Riet J, Oole E, van Ijcken WFJ, van de Werken HJG, Demmers JA, Fodde R, Verrijzer CP.

Cell Rep. 2017 Jul 5;20(1):61-75. doi: 10.1016/j.celrep.2017.06.020.

47.

microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.

van Agthoven T, Eijkenboom WMH, Looijenga LHJ.

Cell Oncol (Dordr). 2017 Aug;40(4):379-388. doi: 10.1007/s13402-017-0333-9. Epub 2017 Jun 13.

48.

Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline.

Giannoulatou E, Maher GJ, Ding Z, Gillis AJM, Dorssers LCJ, Hoischen A, Rajpert-De Meyts E; WGS500 Consortium, McVean G, Wilkie AOM, Looijenga LHJ, Goriely A.

PLoS One. 2017 May 22;12(5):e0178169. doi: 10.1371/journal.pone.0178169. eCollection 2017.

49.

A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort.

Utomo WK, Looijenga LH, Bruno MJ, Hansen BE, Gillis A, Biermann K, Peppelenbosch MP, Fuhler GM, Braat H.

Mol Ther Nucleic Acids. 2016;5:e350. doi: 10.1038/mtna.2016.61.

50.

P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.

van Olphen SH, Biermann K, Shapiro J, Wijnhoven BP, Toxopeus EL, van der Gaast A, Stoop HA, van Lanschot JJ, Spaander MC, Bruno MJ, Looijenga LH.

Ann Surg. 2017 Feb;265(2):347-355. doi: 10.1097/SLA.0000000000001625.

PMID:
28059963

Supplemental Content

Loading ...
Support Center